Endurance Wealth Management Inc. acquired a new stake in shares of Celgene Co. (NASDAQ:CELG) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 6,470 shares of the biopharmaceutical company’s stock, valued at approximately $943,000.
Several other institutional investors and hedge funds have also modified their holdings of CELG. Thompson Davis & CO. Inc. grew its position in Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares during the period. Arcadia Investment Management Corp MI grew its position in Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 400 shares during the period. Motco grew its position in Celgene by 19.3% during the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 159 shares during the period. Penserra Capital Management LLC acquired a new stake in Celgene during the 2nd quarter worth about $129,000. Finally, Balentine LLC grew its position in Celgene by 83.5% during the 2nd quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 481 shares during the period. Hedge funds and other institutional investors own 79.74% of the company’s stock.
CELG has been the topic of a number of analyst reports. Vetr upgraded Celgene from a “hold” rating to a “buy” rating and set a $146.58 target price on the stock in a research report on Friday, October 6th. Royal Bank of Canada restated a “buy” rating and set a $173.00 target price on shares of Celgene in a research report on Thursday, October 5th. Cantor Fitzgerald restated a “buy” rating and set a $162.00 target price on shares of Celgene in a research report on Tuesday, September 26th. Robert W. Baird reiterated a “buy” rating and issued a $162.00 price objective on shares of Celgene in a report on Thursday, September 21st. Finally, Jefferies Group reiterated a “buy” rating and issued a $160.00 price objective on shares of Celgene in a report on Friday, September 15th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and nineteen have given a buy rating to the company. Celgene currently has an average rating of “Buy” and an average target price of $131.18.
Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. Celgene had a net margin of 30.06% and a return on equity of 43.32%. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.58 earnings per share. analysts predict that Celgene Co. will post 6.68 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://stocknewstimes.com/2018/01/12/endurance-wealth-management-inc-buys-new-stake-in-celgene-co-celg.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.